1. HCP_Modal

Influenza imposes a heavy burden on the United States1

Approximately 16 to 64 million individuals in the US are infected with influenza every year, resulting in1,2:

44 MILLION

Days of Lost Productivity3

~ 200,000

Patients Hospitalized4

31 MILLION

Physician Visits3

3.1 MILLION

Hospitalization Days3

Influenza has a significant impact on children and adults5

  • The Influenza Incidence Surveillance Project showed that influenza-like illness (ILI) affects all ages5
Outpatient Visits Related to Influenza Virus for Ages 2-49 Years

For every 100 schoolchildren, influenza resulted in:

Days of Missed School Due to Influenza
Missed Days of Work for Parents
 
 

Up to 20% of the population is infected with influenza each year1

Both influenza A and B contribute to seasonal outbreaks7

 
Proportion of circulating A and B strains in recent influenza seasons in the US

B-lineage mismatch in the 2015-2016 flu season

Update from the Centers for Disease Control and Prevention

blineagemobile

B Lineage Mismatch in the 2005-2006 Influenza Season

With coverage from both B lineages, a quadrivalent vaccine
can help reduce B-lineage mismatch and may help reduce the overall
burden of influenza8
 

Important Safety Information

  • FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy

  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist (Influenza Vaccine Live, Intranasal)

  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing

  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks

  • FluMist Quadrivalent has not been studied in immunocompromised persons

  • The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established

  • FluMist Quadrivalent may not protect all individuals receiving the vaccine

  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat

INDICATION FOR USE

FluMist Quadrivalent is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

Please see full Prescribing Information for FluMist Quadrivalent, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.